Role of Coenzyme Q10 in Prophylaxis of Myocardial Infarction

Abstract

Introduction: Coenzyme Q10 (CoQ10) has a potential role in reducing the risk of myocardial infarction by slowing the progression of atherosclerosis and improving ischemia. In this study, we will assess the role of coenzyme Q10 in prophylaxis for reducing myocardial infarction and mortality related to myocardial infarction. Methods: This open-label two open placebo-controlled randomized clinical trial was conducted in a tertiary care hospital in Sukkur, Pakistan from April 2016 to September 2019. Eight hundred nighty-two (892) patients with clinically diagnosed and documented evidence of hypertension were enrolled in the study from the outpatient department. Participants were randomized into two groups by 1:1 ratio using an online randomizer software, Research Randomizer ( https://www.randomizer.org /). Group A received 100 mg coenzyme Q10 daily (coenzyme Q10 group) in addition to standard therapy and group B received standard therapy only (placebo group). Results: Participants who received coenzyme Q10 had fewer incidence of non-fatal myocardial infarction over 12 months (5.4% vs 8.4%) with relative risk reduction of 2.92 (confidence interval 95%, 0.55-2.76). The number needed to treat to prevent one non-fatal myocardial infarction was 34. Participants who received coenzyme Q10 had fewer incidence of fatal myocardial infarction over 12 months (1.5% vs 3.1%) with relative risk reduction of 1.65 (confidence interval 95%, 0.39-3.69). Number needed to treat to prevent one fatal myocardial infarction was 60. Conclusion: According to this study, coenzyme Q10 reduced the incidence of fatal and non-fatal myocardial infarctions. Clinicians should consider adding coenzyme Q10 to the treatment regimen of high-risk patients of myocardial infarction. We suggest coenzyme Q10 may be an effective prophylactic agent in patients at risk of myocardial infarction and it may help in reducing burden on the health care system.

Correlation of Coenzyme Q10 with MDA in Iraqi Patients with Myocardial Infarction

“…In addition, CoQ10 inhibits the atherosclerosis process and reduces inflammation by limiting the oxidation of low-density lipoprotein (LDL). (Shah et al, 2021).Patients with ischemic heart disease have been reported to have significantly lower blood levels of CoQ10 than healthy people (Kumar et al, 2009).The present study has demonstrated that serum CoQ10 levels were reduced in patients with MI as compared to control subjects, this result is similar to the results of a study on patients with coronary artery disease, which observed that the patients had significantly decreased plasma coenzyme Q10 levels compared to healthy controls (Lee et al, 2012). Plasma concentrations of CoQ10 were significantly lower in patients with ischemic heart disease and dilated cardiomyopathy compared to healthy individuals (Langsjoen et al, 1990).…”

Engineered Biomimetic Nanoplatform Protects the Myocardium Against Ischemia/Reperfusion Injury by Inhibiting Pyroptosis

“…12 It was found 10 that a great number of chemical groups (such as imine, amine, and catechol) present on the surface of polydopamine nanoparticles (NPs) could scavenge multiple ROS including H 2 O 2 , • OH, and ONOO−. Compared with traditional antioxidants such as coenzyme Q 13 and vitamin C, 14 PDA exerts a more stable antioxidant effect against MI due to its unique nanostructure. However, dynamic contraction−relaxation cycles and the rapid blood flow rate of the heart make it difficult to retain sufficient PDA inside the heart for a prolonged time, which may diminish its therapeutic efficacy in MI/RI.…”